FDA’s new expert panels are rife with financial conflicts and fringe views
FDA panel debated adding a black box warning for SSRIs in pregnancy despite evidence showing benefits outweigh risks for 5-6% of pregnant North American women.
- As clinicians, the authors have witnessed the maternal mental health crisis in the U.S., where mental illness is the leading cause of maternal deaths.
- Research shows the benefits of SSRIs for pregnant patients outweigh the risks, and the risks of untreated depression are very serious, including higher risks of preterm birth, low birth weight, and suicide.
- The FDA-convened panel heavily focused on potential risks of SSRI usage during pregnancy, with some individuals incorrectly asserting these drugs cause autism and birth defects, contradicting research showing they are not associated with such conditions.
35 Articles
35 Articles

FDA's new expert panels are rife with financial conflicts and fringe views
A series of panels convened by the Food and Drug Administration is raising concerns that the agency is skirting federal rules and promoting fringe views about antidepressants and other products.
FDA panel has cast doubt on whether antidepressants are safe in pregnancy. Here's what the science actually says.
Decades of research show that SSRIs can be safely used during pregnancy. Meanwhile, untreated depression during pregnancy is associated with poor health outcomes like preterm birth and preeclampsia.
Antidepressants & Pregnancy: FDA Panel & Latest Research – Archyde
Archyde The Looming Shadow Over Maternal Mental Health: Why an FDA Warning on SSRIs Could Backfire The maternal mental health crisis in the United States is already claiming lives, with suicide… You can read the full story here: Antidepressants & Pregnancy: FDA Panel & Latest Research.
Coverage Details
Bias Distribution
- 81% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium